JBIO (aerovatetx.com) Net Profit

JBIO (aerovatetx.com) - company brandmark

This daily price chart for Aerovate Therapeutics Inc (JBIO) reflects profit dynamics currently priced in at -0.14. The business focuses on developing treatments for pulmonary hypertension, anticipating global revenue driven by patent protection and low synthesis costs. However, the company is currently undergoing clinical trials and a strategic review, lacking stable profit streams and relying solely on existing reserves.

JBIO (Aerovate Therapeutics Inc) Net Profit history from 04/30/2025 to 11/01/2026

Analytical breakdowns and data insights for company aerovatetx.com (JBIO)

- price and consensus price forecast:
Stock Quotes Aerovate Therapeutics|JBIO - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization JBIO|JBIO - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Aerovate Therapeutics Inc|JBIO - Book Capitalization|Market Capitalization to Book Value aerovatetx.com|JBIO - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Aerovate Therapeutics Inc|JBIO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Aerovate Therapeutics|JBIO - Company Total Debt|Debts to Book Capitalization JBIO|JBIO - Company Long-Term Debt|Company Short-Term Indebtedness Aerovate Therapeutics Inc|Immediate Liquidity aerovatetx.com
- net income and valuation multiples indicators:
JBIO - Net Profit
Summary company analysis:Aerovate Therapeutics Inc
Core merchandise of Aerovate Therapeutics, Inc.

Net income reflects the final financial result after deducting all operating and tax expenses. Investors analyze this metric to assess the speed of business capitalization and its resilience to monetary shocks. The trend in net income levels allows for the determination of the efficiency of internal resource management. For Aerovate Therapeutics Inc (JBIO), this indicator is secondary to R&D. The success of developing a drug for pulmonary hypertension depends on clinical data rather than market cycles.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|Intrexon - Net Profit|PHAR - Net Profit|NKTR: Net Profit|Company Net Income upstreambio.com (UPB)|Company Net Income Zenas Biopharma|IMNM: Final Profit|Company Net Income Gossamer Corp (GOSS)|KALV - Company Net Income|Septerna Inc - Net Income|pieris.com - Company Net Income|Savara - Net Profit|RIGL - Net Profit|ANAB (AnaptysBio Corp) - Net Income|ATXS: Profit After Payment of Taxes|ENGN (enGene Holdings Inc.) - Net Profit|Company Net Income rapt.com RAPT|Net Income ACRS (Aclaris Therapeutics, Inc.)|KYTX (Kyverna Therapeutics Inc.) - Final Profit|Tiziana Life Sciences PLC - Net Income|Profit After Payment of Taxes CABA (Cabaletta Bio Inc)|Ventyx Biosciences - Net Profit|Final Profit THTX (theratech.com)|AVTX: Net Profit|Company Net Income Eledon Pharmaceuticals Inc. (ELDN)|Company Net Income Agenus Inc|CLYM: Final Profit|Net Profit ZURA|Net Profit atyrpharma.com (ATYR)|Company Net Income Adagene Inc. ADAG|IMA (ImageneBio) - Profit After Tax|Shattuck Therapeutics - Net Profit|Company Net Income Equillium, Inc.|CNTB (connectbiopharm.com) - Net Income|Immunic (IMUX) - Net Profit|Net Income ATRA|IFRX (InflaRx GmbH) - Profit After Payment of Taxes|Net Profit XFOR|Net Financial Result adicetbio.com|Net Profit CELU (Celularity)|INMB - Net Income|BRNS - Company Net Income|Net Financial Result Kezar Life Sciences Inc. KZR|SABS (SAB Biotherapeutics, Inc) - Net Income|Akari Therapeutics, Plc - Final Profit|ENLV (Enlivex Therapeutics Ltd) - Net Profit|Q32 Bio Corp (QTTB) - Net Financial Result|Company Net Income GeoVax (GOVX)|Edesa Biotech Inc - Company Profit|Net Profit IBIO (iBio Corp)|CARM - Net Income|XTLB - Company Net Income|Bolt Biotherapeutics - Profit After Payment of Taxes|HCWB: Net Profit|APVO (Aptevo Therapeutics Inc.) - Company Net Income|AIM (AIM ImmunoTech) - Net Profit|Aditxt Corp (ADTX) - Net Financial Result|Company Net Income GRI Bio, Inc. (GRI)|XRTX - Company Net Income|Company Net Income Vyome Holdings HIND|REVB (Revelation Biosciences Inc) - Profit After Tax|Indaptus - Net Profit|Final Profit SCNI (BiondVax Pharmaceuticals)|CALI: Net Profit|Affimed N.V. (AFMD) - Net Profit|Company Net Income Allakos Inc|HOOK: Final Profit|Company Net Income IGM Biosciences, Inc. (IGMS)|Net Income iTeos Pharma ITOS|Net Profit OCEA (Ocean Biomedical, Inc.)|Net Profit tcbiopharm.com TCBP|THRD: Net Income